



Last day of trading in Series TO 2 B subscription warrants

The exercise period of the Series TO 2 B subscription warrants issued in connection with the rights issue of units that Calmark Sweden AB (publ) carried out during November 2019 runs until and including December 16, 2020. The last day of trading in Series TO 2 B subscription warrants on Spotlight Stock Market is December 14, 2020. Holders of Series TO 2 B subscription warrants are entitled, for each warrant, to subscribe for one new B share in Calmark at a price of SEK 4.44 per B share. On full exercise of all Series TO 2 B subscription warrants, 2,455,560 new B-shares will be issued, and Calmark will raise approximately MSEK 10.9 before issuance costs.

Instructions on how to subscribe for B shares are provided in the press release published by Calmark on December 4, 2020, and on Calmark's website, www.calmark.se.

If your subscription warrants are registered in the name of a nominee (e.g., holdings in securities custody services such as Nordnet or Avanza, investment savings accounts (ISK) or endowment insurances), please contact your trustee to subscribe. Note that procedural delays may vary.

If your subscription warrants are registered directly (holdings in securities accounts), you have to download and fill out an application slip, which is available at www.hagberganeborn.se.

Please note that Series TO 2 B subscription warrants expire worthless if not actively used to subscribe for shares no later than December 16, 2020, or sold no later than December 14, 2020.

Financial advisors

Stockholm Corporate Finance AB is the financial advisor, Stenbergets Avtalslösningar AB is the legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing agent of Calmark in connection with the exercise period.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

About Calmark Sweden AB

(publ)
Calmark is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.

About Stockholm Corporate Finance

Stockholm Corporate Finance is a Swedish, independent and privately-owned financial advisor offering qualified transaction based advisory services by acting in capital raisings, changes in ownership, acquisition, merger and acquisitions (M&A) in listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network of M&A Worldwide consisting of 46 M&A advisors and investment banks in 38 countries. Stockholm Corporate Finance is an investment firm which is supervised by the FSA and is a member of the trade organization SwedSec Licensing AB. www.stockholmcorp.se.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93

E-post: anna.soderlund@calmark.se

www.calmark.se